Immuno-Designed Molecules

Immuno-Designed Molecules
Paris, France
Founded: 1993

Why It's Fierce: IDM is our top pick in the resurgent cancer vaccine field. The company's Cell Drugs combine two cell groups to create a customized therapy for strengthening the body's immune response to cancerous antigens. With five drugs in late stage clinical development, IMD has reached the make or break stage of its business model. We're optimistic the company will make good on the promise of cancer vaccines.

What to look for in 2003: Results of a Phase III ovarian cancer vaccine study should be announced shortly.

Immuno-Designed Molecules

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.